B. Riley Securities Reiterates Buy on Altimmune, Lowers Price Target to $11

Benzinga · 2d ago
B. Riley Securities analyst William Woods reiterates Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $13 to $11.